It is recognised that stromal cells determine cancer progression. We have previously shown that active TGFb produced by rat colon carcinoma cells modulated NO production in rat endothelial cells. To elucidate the role of TGFb and NO in the mechanisms of interaction of colon carcinoma cells with stromal cells and in cancer progression, we transfected REGb cells, a regressive colon carcinoma clone secreting latent TGFb, with a cDNA encoding for a constitutively-secreted active TGFb. Out of 20 injected rats only one tumour progressed, which was resected and sub-cultured (ReBeta cells). ReBeta cells secreted high levels of active TGFb. The adhesive properties of REGb and Rebeta cells to endothelial cells were similar, showing that the secretion of active TGFb is not involved in tumour cell adhesion to endothelial cells. ReBeta, but not REGb, cell culture supernatants inhibited cytokine-dependent NO secretion by endothelial cells, but inhibition of NO production was similar in co-cultures of REGb or ReBeta cells with endothelial cells. Therefore, secretion of active TGFb regulated endothelial NO synthase activity when tumour cells were distant from, but not in direct contact with, endothelial cells. However, only ReBeta cells inhibited cytokine-dependent secretion of NO in coculture with macrophages, indicating that the active-TGFb-NO axis confers an advantage for tumour cells in their interaction with macrophages rather than endothelial cells in cancer progression.
Introduction
To progress and successfully metastasise tumour cells have to resist defence mechanisms of the host organ stromal cells. Nitric oxide (NO) derived from macrophages and endothelial cells has been shown to reduce adhesion of tumour cells to endothelial cells and participates in tumouricidal activity against many types of tumours [1] [2] [3] [4] [5] [6] [7] [8] . Cells, including macrophages and endothelial cells, express an inducible form of NO synthase (iNOS) [9] which has been involved in defence mechanisms against pathogens and tumour cells. Consequently, the capacity of tumour cells to modulate the level of NO production at the metastasis site could be crucial in regulating adhesive properties and survival of tumour cells and may determine the outcome of cancer metastasis.
TGFb has been involved in the mechanisms regulating tumour progression. However, the function of TGFb in cancer depends on the tumour stage and context [10] . In early stages TGFb is anti-tumoural, inhibiting proliferation of tumour cells, whereas in later stages, TGFb signalling pathways in tumour cells are inactivated. TGFb then promotes cancer progression, acting as a permissive factor for stromal cells, inhibiting host immune surveillance, stimulating invasion, angiogenesis and metastasis. TGFb also regulates protease secretion, including matrix metalloproteases (MMPs), or tumour cell interaction with endothelial cells [11] [12] [13] . We have previously shown that a progressive clone (PROb cells) of a chemically-induced rat colon carcinoma, secreting active TGFb inhibited NO synthase induction and NO secretion in rat EC219 endothelial cells, whereas a regressive clone (REGb cells) isolated from the same colon carcinoma, secreting only latent TGFb did not regulate NO production by EC219 cells [14] . In order to elucidate the role of tumour cell-derived TGFb in the TGFb-NO axis in cancer progression, we transfected REGb cells with a constitutively-secreted active form of TGFb and evaluated the potential for these cells to form progressive tumours in vivo in tumour-cells syngeneic rats and to interact in vitro either with endothelial cells or macrophages expressing functional TGFb receptors.
Materials and methods

Cell lines
The development and characterisation of the rat EC219 endothelial cell line have been described [15] . Cells were grown in Dulbecco's modified Eagle's medium (DMEM, 1 g/l glucose; Life Technologies, Basel, Switzerland) supplemented with 10% Fetal Calf Serum (FCS; Seromed, Fakola, Basel, Switzerland) and antibiotics on collagen type-I (Serva, Wallisellen, Switzerland) coated flasks. DHD/K12/TRs (referred to as REGb), a generous gift from Prof. F. Martin (INSERM, University of Dijon, France), is a sub-clone of the chemically induced rat colon carcinoma cell line DHD/K12. REGb cells form regressive tumours when inoculated into syngeneic BD-IX rats [16] . ReBeta cells are REGb cells which have been transfected with the cDNA encoding for active TGFb and selected in vivo (see below). REGb and ReBeta cells were grown in 1:1 DMEM-HAM-F12 (Life Technologies) supplemented with 10% FCS and antibiotics. To prepare cell culture conditioned media (CM), cells were grown in culture media containing 10% FCS until reaching 75% confluence, then cultured for 48 h in serum-free culture medium. The culture supernatants were collected and spun for 10 min at 200 Â g and the supernatants recovered. CCL-64 cells (a kind gift from Dr K. Frei, Department of Neurosurgery, University Hospital Zurich, Switzerland) is a mink-lung epithelial cell line whose proliferation is inhibited by TGFb. CCL-64 cells were grown in DMEM supplemented with 5% FCS and 50 lM b-mercaptoethanol (Sigma, Buchs, Switzerland).
Isolation and culture of bone marrow-derived macrophages
Bone marrow-derived macrophages (BMDM) were isolated from the femur and tibia of adult rats (OFA/ SPF; BRL, Fu¨llingsdorf, Switzerland). The bone-heads were cut and the bone marrow was collected by rinsing the bone cavity with 5 ml DMEM with a 25 G needle. Resulting cell suspension was spun at 100 Â g for 5 min.
Cells were cultured in Sterilin petri dishes (Bibby Sterilin, Ostermundigen, Switzerland) in a differentiation culture medium consisting of 50% DMEM 1 g/l glucose, 30% culture supernatant of L929 mouse fibroblasts and 20% horse serum (Life Technologies) and antibiotics. After 7 days, cells were detached by incubation for 30 min at 4°C and were further expanded in the differentiation culture medium for 5 days. BMDM were then washed with PBS and cultured in DMEM supplemented with 10% FCS for 24 h, before performing experiments.
Transfection of REGb cells
Mutation of the Cys223 and Cys225 to Ser [17] induces the production of TGFb1 peptides which do not associate with the latency associated peptide resulting in the secretion of constitutively biologically active TGFb1. Five microgram of a PCRIII vector encoding mutated porcine TGFb1, or a void vector as control, in 50 ll of 20 mM Hepes, pH 7.4 were adsorbed for 15 min at room temperature onto the DOTAP Liposomal Transfection Reagent (Roche Diagnostics, Rotkreuz, Switzerland) at 30 lg/ml final concentration under the conditions described by the provider. Then 5 ml DMEM were added and the resulting suspension was added to half-confluent REGb cells. The cells were incubated for 4 h at 37°C, washed and grown in DMEM containing 10% FCS for 5 days. Then transfected cells were selected for 2 weeks in the presence of 800 lg/ml neomycin (Sigma), sub-cloned and grown in DMEM-HAM-F12 (1:1) containing 10% FCS. The production of active TGFb was measured using the CCL-64 cell growth-inhibition assay (see below).
Animal experimentation
Two clones of TGFb-transfected REGb cells were selected (see Table 1 ) depending on their level of secretion of active TGFb (determined using the CCL-64 cell growth-inhibition assay) and on their capacity to inhibit iNOS activity in EC219 cells. Parental or transfected REGb cells (transfected either with a void vector or the vector containing the cDNA encoding active TGFb) were injected subcutaneously (10 6 cells in 500 ll PBS per rat) into syngeneic BD-IX rats (10 rats/group; brothersister mated since 1971 in the laboratory of Prof. F. Martin). Tumour growth was evaluated weekly for 10 weeks by measuring width and length of the tumour mass using calipers. The rats were then sacrificed. As previously described, REGb cells always regressed when injected under these conditions [16] . The only growing tumor arising from the injection of active TGFb1-transfected REGb cells was resected 10 weeks after injection, enzymatically digested to yield single cell suspension and expanded in vitro under the name ReBeta cells. Their secretion of active TGFb was measured using the CCL-64 cell growth-inhibition assay and ELISA for active TGFb.
Inhibition of NO induction in EC219 cells
These experiments were performed essentially as previously described [14] . Briefly, confluent EC219 cells were simultaneously exposed to 40 U/ml rat IFN-c (rIFN-c, Immunogenetics, Antwerpen, Belgium) and 200 U/ml murine TNF-a (mTNF-a, Roche), respectively and, when indicated, the culture supernatants of untransfected or transfected REGb cells for 24 h. Then NO secretion in the EC219 cell culture medium was quantified as nitrites using the Griess reagent as previously described [14] . To verify the induction of iNOS by cytokines in these cells, Western blotting experiments were performed using with an anti-mouse iNOS antibody (Transduction Laboratories, Basel, Switzerland).
CCL-64 cell growth-inhibition assay for TGFb quantification
CCL-64 cells (5 Â 10 4 per well) were incubated for 72 h at 37°C in 96-well microtiter plates with serial dilutions of unknown samples or recombinant human TGFb1 (rhTGFb; R&D Systems, Abingdon, UK) at increasing concentrations (5 pg/ml to 1 ng/ml rhTGFb). Cell proliferation was assessed by addition of 250 lg/ml MTT [3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Sigma) in DMEM during the last 2 h. MTT crystals were dissolved with 0.04 N HCl in isopropanol and optical density was measured at 540 nm in a multiwell microtiter plate reader (Labsystems iEMS Reader MF). TGFb1 activity (pg/ml) in the samples was determined by comparison with a rhTGFb standard curve. Latent TGFb was activated by heating the samples at 95°C for 3 min, as previously described [14] , then active peptide determined using the CCL-64 cells.
Determination of TGFb protein level by ELISA
Secreted TGFb1 protein was measured in cell culture conditioned media using paired antibodies cross-reacting with rat and porcine TGFb1 (R&D Systems) according to the manufacturer's instructions. Ninetysix-well microtiter plates were coated with capture antibody (MAB 240; 4 lg/ml in 100 ll PBS) and unknown or rhTGFb1 (5 pg/ml to 5 ng/ml rhTGFb) diluted in 20 mM Tris containing 150 mM NaCl, 0.1% BSA and 0.05% Tween 20 (diluent solution) were added and incubated for 2 h at room temperature, then biotinylated detection antibody (BAF 240; 50 ng/ml in diluent solution) was incubated for 2 h at room temperature. Quantification was done with peroxydasecoupled Streptavidin (62.5 ng/ml in diluent solution, Zymed Laboratories, San Francisco, CA), 0.006% H 2 O 2 and 100 mg/ml tetramethylbenzidine (Sigma) in 0.05 M phosphate-citrate buffer. The reaction was stopped with 0.5 M H 2 SO 4 and optical density was measured at 450 nm using a reference filter at 620 nm in a multiwell microtiter plate reader (Labsystems). Concentrations of TGFb1 in samples were calculated by comparison with a standard curve using rhTGFb.
NO and TGFb secretion by REGb and ReBeta cells under cytokine stimulation
Cells were exposed to 40 U/ml rIFN-c, 200 U/ml mTNF-a and 500 pg/ml rat IL-1b (rIL-1b, R&D system, Abingdon, UK) for 24 h and NO or TGFb secretion in the cell culture medium was quantified as nitrites using the Griess reagent as previously described [14] , or using the CCL-64 cell growth inhibition assay, for NO or TGFb, respectively.
Co-cultures of tumour cells with of endothelial cells or macrophages
EC219 endothelial cells were plated alone or together with either REGb or ReBeta tumour cells in 48-well plates (2.5 Â 10 4 EC219 cells and/or 5 Â 10 4 tumour cells per well). Cells were allowed to adhere overnight at 37°C and stimulated with 40 U/ml rIFN-c plus 200 U/ ml mTNF-a for 24 h in complete culture medium. Culture supernatants were collected and nitrite concentrations determined using the Griess reagent [14] . Bone marrow-derived macrophages were plated in 48-well plates 24 h prior to addition of REGb or ReBeta tumour cells (5 Â 10 4 cells per well). After 24 h, cells were activated with 40 U/ml rIFN-c plus 100 ng/ml Lipopolysaccharide (LPS; Sigma) for 24 h in the presence of REGb transfected clones were grown to 75% confluence and culture medium was conditioned for 3 days in the absence of FCS. TGFb content in the cell culture media was determined using either the CCL-64 growth inhibition assay, or the inhibition of NO secretion by EC219 cells or in cocultures of transfected cells with endothelial cells. ++: High levels of active TGFb; +: medium levels of active TGFb; ): below detection limits; ND not determined.
10% FCS. Culture supernatants were collected and nitrite concentrations determined. Cultures of EC219, REGb or ReBeta cells or macrophages alone were used as controls.
Adhesion assay
EC219 cells in 48-well plates were either untreated or treated for 48 h with either 40 U/ml rIFN-c plus 100 U/ ml mTNF-a or with 4 and 2 ng/ml or 400 pg/ml rhTGFb. Cells were washed twice with DMEM without FCS immediately prior to adhesion assay. REGb and ReBeta tumour cells were labelled with 400 nCi/ml 
Zymogram analysis of gelatinase activity
REGb-CM and ReBeta-CM supernatants were prepared as described above and concentrated 30-fold by centrifugation through a 5 kDa cut-off polymer membrane (Millipore AG, Volketswil, Switzerland). Samples (25 lg/lane) were resolved without prior denaturation by electrophoresis in 10% SDS-polyacrylamide gel containing 1 mg/ml gelatin (Merck, Switzerland). As control, recombinant human MMP-2 (rhMMP-2; 4 ng/ lane; Oncogene Research Products, Luzern, Switzerland) was run in parallel. Following electrophoresis, gels were washed free of SDS with 2.5% Triton X-100 (Fluka, Buchs, Switzerland) and incubated at 37°C for 24 h in 50 mM Tris-HCl pH 7.5 containing 200 mM NaCl, 5 mM CaCl 2 and 0.02% Brij-35 (Fluka) and stained in with 0.05% Coomassie Brilliant Blue G-250 (Serva). MMP-2 activity was identified by its comigration with recombinant human MMP-2.
Statistical evaluation
Means, standard deviations (SD) and statistical significance were calculated using a paired Student's t-test.
Results
Rat REGb colon carcinoma cells were transfected either with the cDNA encoding constitutively-secreted active TGFb1 or the empty vector as control. Transfected cells grew at the same rate than parental cells. Following 2 week selection and sub-cloning, constitutive secretion of active TGFb was measured in the culture supernatants of five different clones using the CCL-64 cell growth-inhibition assay, the inhibition of NO secretion by endothelial EC219 cells or by co-cultures of transfected REGb cells with endothelial cells (Table 1) . Clone 3 produced very high levels of active TGFb, as assessed by strong inhibition of CCL-64 cell growth and of NO secretion by EC219 cells and were rejected for animal experimentation to avoid risks of fibrosis. Clones 11 and 16 produced low levels of active TGFb using the CCL-
The secretion of total (latent + active) TGFb by ReBeta and REGb cells was measured using an ELISA ( Table 2) . As previously described [14] , REGb cells secreted nearly detectable levels of active TGFb whereas ReBeta cells secreted very high levels of TGFb. Active TGFb secretion under cytokine stimulation was also determined using the CCL-64-growth inhibition assay resulted in a slight increase of NO secretion only by REGb cells, and the combination of rIFN-c, mTNF-a and IL-1b resulted in a significant increase of NO secretion by both cell lines (P < 0.01) although the cytokine-dependent increase of NO secreton by ReBeta cells was significantly lower than by REGb cells (P < 0.01) (Figure 3 ). ReBeta and REGb cells secreted equivalent amounts of matrix metalloproteinase (MMP)-2, while secretion of MMP-9 was absent in both cells (Figure 4 ). The effects of factors secreted by REGb and ReBeta cells on the secretion of NO by EC219 endothelial cells was evaluated. Treatment of EC219 endothelial cells with 40 U/ml rIFN-c and 100 U/ml mTNF-a for 24 h induced NO release ( Figure 5 ), involving up-regulation of iNOS expression as determined by mRNA level or iNOS activity [14] or by Western Blot (Figure 5, insert) . Addition of ReBeta-cell conditioned medium (ReBeta-CM) to EC219 cells simultaneously with cytokines inhibited NO secretion whereas REGb-cell conditioned medium (REGb-CM) did not ( Figure 5 ). Then the role of tumour cell-secretion of TGFb on rapid adhesion of were grown to 60% confluence, and either not stimulated ()) or stimulated (+) with the indicated cytokines (40 U/ml rIFN-c, 100 U/ml mTNF-a, 500 pg/ml rIL-1b) for 48 h and NO secretion was determined. Statistical significance was assessed using a twotailed paired Student's t-test, *: P < 0.05; **: P < 0.01. rIFN-c plus 100 U/ml mTNF-a or with increasing concentrations of rhTGFb (400 pg/ml up to 4 ng/ml rhTGFb) for 48 h prior to adhesion assay did not modify their adhesive properties for either REGb (Figure 6b) or ReBeta cells (data not shown). In order to eliminate endothelial cell line-specific effects we performed similar experiments using another rat endothelial cell line, the CR3 cells [18] , with similar information (results not shown). Next, the effect of direct contact between REGb or ReBeta cells with endothelial cells on the secretion of active or total TGFb was quantified in the supernatant of co-cultures of EC219 cells with either REGb or ReBeta cells. EC219 cells did not secrete TGFb, no active TGFb and only low levels of latent TGFb were detected in the supernatants of co-cultures of EC219 with REGb cells, whereas the secretion of active TGFb in co-cultures of ReBeta cells with EC219 cells was decreased (Figure 7 ). Finally the effect on NO secretion of direct contact between REGb or ReBeta cells and EC219 endothelial cells or bone marrow-derived macrophages was evaluated. Co-culture of EC219 endothelial cells with either REGb or ReBeta tumour cells did not modulate NO production in the absence of added cytokines (results not shown). However, NO production was inhibited when cytokine-stimulated EC219 cells were in co-cultures with either REGb or ReBeta cells (Figure 8 ). The inhibition of cytokine-induced NO production by EC219 cells can be reversed by addition of a blocking anti-TGFb1 antibody [14] demonstrating the role of TGFb in the inhibition of NO secretion by EC219 cells. Addition of blocking anti-TGFb1 antibody to the cocultures did not restore NO secretion by cytokinestimulated EC219 cells (Figure 8, insert) . Activation of macrophages with rIFN-c and LPS resulted in the secretion of large amounts of NO (Figure 9a ). When macrophages were in contact with REGb cells, NO secretion was not modified, however in contact with ReBeta cells, NO secretion was inhibited, suggesting that the levels of active TGFb secretion by colon carcinoma cells is involved in the regulation of production of NO by macrophage, but not by endothelial cells. Pre- Figure 8 . NO production in co-cultures of endothelial cells with either REGb or ReBeta cells. EC219, REGb or ReBeta cells were grown either alone (EC219, REGb, ReBeta) or in co-culture (EC219 + REGb, EC219 + ReBeta) for 24 h, then either untreated (light grey bars), or stimulated with 40 U/ml IFN-c and 100 U/ml TNF-a (dark grey bars) for 24 h, and NO secretion was determined. Statistical significance was assessed using a two-tailed paired Student's t-test, *: P < 0.05; **: P < 0.01; ***: P < 0.001. Results are means of duplicate wells ±SD of one representative experiment out of 3. Insert: In co-cultures of EC219 cells with either REGb (REGb) or ReBeta (ReBeta) cells, addition of an anti-TGFb-blocking antibody did not restore NO secretion in response to cytokines. White bars: cytokines; grey bars: cytokines + anti-TGFb antibody.
treatment of macrophages for 24 h prior to rIFN-c and LPS stimulation was not able to inhibit their NO secretion (Figure 9b ).
Discussion
TGFb family ligands signal through a common mechanism bringing together type I and type II Ser/Thr kinase receptors, resulting in the phosporylation of type I receptor by type II receptor and activation of intracellular signalling pathways. Colon cancer cells predominantly produce TGFb in a latent form [19] . TGFb is secreted as a latent complex of 290 kDa consisting of bioactive TGFb (Mr 25 kDa), the latency-associated peptide (LAP; Mr 75 kDa), and the latent TGFb binding protein 1 (LTBP1; Mr 190 kDa). LTBP1 is attached to LAP by a disulfide bond, which is required for the assembly and secretion of the latent TGFb complex and prevents TGFb signalling [20] . Mutations of Cys223 and Cys225 to Ser in the propeptide region of TGFb1 precursor [17] result in TGFb1 peptides which do not associate to the LAP, and secretion of constitutively biologically active TGFb1. TGFb has been proposed to favour tumour progression in colon carcinoma but its contribution has not been clearly established. TGFb is a potent growth inhibitor for normal epithelial cells, whereas in carcinoma cells, including colon cancer cells, mutations in the genes encoding TGFb receptors frequently inactivate signalling [21] . TGFb produced by tumour cells also exerts a paracrine effect on tumour stroma [12] . Therefore in the early stages of cancer TGFb is anti-tumoural, inhibiting proliferation of tumour cells, whereas in later stages, TGFb rather promotes cancer progression by acting as a permissive factors for stromal cells to inhibit host immune surveillance, and stimulate invasion, angiogenesis and metastasis.
In the present experiments, in order to address the role of the interplay between TGFb and NO in cancer progression, we tested the hypothesis that the levels of active-TGFb secretion by tumour cells is involved in stromal cell functions, particularly in modulating tumour cell interaction with endothelial cells and macrophages. To evaluate this hypothesis, we decided to perform in vivo selection of REGb cells engineered to secrete high levels of active TGFb, then to perform in vitro studies, comparing REGb cells with active-TGFbtransfected REGb cells which had demonstrated the capacity for in vivo progression. Therefore REGb cells were transfected with a cDNA encoding constitutivelysecreted active TGFb and these modified REGb cells were injected in syngeneic rats. The in vivo progression of tumour cells was evaluated and the interaction in vitro of a progressive tumour, ReBeta cells, with endothelial cells and macrophages was analysed in relation with tumour cell-dependent secretion of TGFb and regulation of NO production.
Our results demonstrated that the secretion by colon carcinoma cells of high levels of active TGFb is not sufficient for a high incidence of tumour progression since out of 20 animals only one harboured a progressive tumour, which after resection still secreted high levels of TGFb. With the present approach we cannot ascertain whether the expression of the transfected peptide was maintained in the 19 animals which did not develop tumours. The autocrine secretion of high levels of active TGFb did not inhibit growth of TGFb-transfected REGb cells, suggesting the loss of responsiveness of these cells for this effect of TGFb. After in vivo progression of TGFb-transfected REGb cells, cytokine activation further increased their TGFb secretion, but decreased their production of NO compared to REGb cells. Levels of active TGFb secretion in this model did not modify MMP-2 production, therefore excluding a role for TGFb in promoting cancer progression via this pathway, which is in accordance with the information that tumour-associated fibroblasts are the main source of MMPs in tumours. NO has been shown to increase tumour cells adhesion to cytokine-stimulated endothelial cells [3] , or to reduce tumour cell adhesion to postcapillary venules [6] melanoma cells secreting latent TGFb enhanced adhesion of tumour cells to endothelial cells [22] . Our present results demonstrated that the levels of active TGFb secretion by colon carcinoma cells and the modulation by TGFb of NO secretion by endothelial cells did not modify adhesive properties between endothelial and tumour cells, irrespective of cytokine stimulation of endothelial cells. In our model, the absence of modulation of tumour cells adhesion to cytokine-activated endothelial cells suggested that the interactions of colon carcinoma cells with endothelial cells are not based on the modulation by cytokines of the adhesive properties of adhesion molecules. In agreement with these results we have previously shown in a breast cancer model of lung metastasis that NO did not influence the early stages of tumour metastasis and the interaction of invading tumour cells with pulmonary endothelial cells, but that the cellular origin of NO was critical to the metastatic process [23] . Progressive colon carcinoma cells (PROb cells) secreting active TGFb had the ability to inhibit cytokine-induced NO production in EC219 endothelial cells and microglial cells while a regressive clone (REGb cells) isolated from the same carcinoma but secreting only latent TGFb did not display these properties [14] . In PROb cells, regulation of NO secretion by TGFb was an intracrine process, whereas exogeneously added TGFb was ineffective [24] . The activation of latent TGFb has been shown to be mediated by direct contact between endothelial and smooth muscle cells [25] . In co-cultures of EC219 with REGb or ReBeta cells, both cell lines behaved comparably, suggesting that latent TGFb could be activated through intercellular mechanisms. Tumour-cell derived IFN-b stimulates NO production by host cells, including macrophages, and suppresses tumour progression [26] . TGFb is able to block cytokine-mediated activation of macrophages and their NO secretion [27, 28] and is involved in the suppression of local immune response and NO-mediated macrophage cytotoxicity. Therefore tumour progression was inversely related to NO secretion by macrophages [29] . In our model, the level of TGFb secretion, and the resulting modulation of NO secretion by macrophages was important in the mechanisms of interaction of colon carcinoma cells with macrophages. The decreased secretion of NO could be due to the blockade of macrophage activation by high levels of active TGFb secreted by ReBeta cells, but not REGb cells. However, pre-exposure of macrophages to rhTGFb before rIFN-c and LPS stimulation failed to mimic this inhibitory effect. These results suggest that continuous presence of high levels of TGFb, as achieved in co-culture of macrophages with ReBeta cells, is necessary for this effect, or that direct contact, or alternatively that other molecules, are involved.
In conclusion, our study demonstrates that the secretion of high levels of active TGFb is not sufficient to generally allow colon carcinoma cells to progress in vivo. These results also demonstrate that the adhesion of tumour cells to endothelial cells does not depend on the level of secretion of active TGFb by tumour cells, suggesting that the NO-modulated adhesion of tumour cells to the endothelium is not a limiting factor for progression. The inhibition of NO production in macrophages depended on the level of active TGFb secreted by tumour cells, indicating that immunomodulation of the host defence mechanisms by high TGFb and the resulting modulation of the TGFb-NO axis may be related to tumour progression.
